Axillary Surgical Attitude Changing with Retrospective Application of
Breast-conserving surgery
axillary lymph node dissection
axillary surgery
sentinel lymph node biopsy
seroma
Journal
European journal of breast health
ISSN: 2587-0831
Titre abrégé: Eur J Breast Health
Pays: Turkey
ID NLM: 101709357
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
28
06
2023
accepted:
14
09
2023
medline:
5
10
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
epublish
Résumé
Sentinel lymph node biopsy (SLNB) represents the gold standard for axillary surgical staging. The aim of this study was to assess the proportion of axillary lymph node dissection (ALND) that could be avoided after retrospective application of the We reviewed breast cancer (BC) patients treated by primary breast-conserving surgery from 2012 to 2015. The percentage of SLNB vs ALND performed before and after the application of the Two hundred fifty one patients with a median age of 59.3 years were included. BC tumors had a median size of 13 mm and were mostly unifocal (83.9%). There were 30.3% with 1-2 metastatic lymph nodes (MLN). ALND was performed in 44.2%. The patients with 1-2 MLN, had only SLNB in 14.5% of cases. By applying the SNLB is the most commonly used axillary surgical staging procedure in this series (55.8%). With a retrospective application of the
Identifiants
pubmed: 37795004
doi: 10.4274/ejbh.galenos.2023.2023-6-4
pii: 62275
pmc: PMC10546802
doi:
Types de publication
Journal Article
Langues
eng
Pagination
318-324Informations de copyright
©Copyright 2023 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
Ann Oncol. 2009 Jun;20(6):1001-7
pubmed: 19174453
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Medicina (Kaunas). 2021 Nov 19;57(11):
pubmed: 34833492
Ann Oncol. 2021 Oct;32(10):1216-1235
pubmed: 34242744
N Engl J Med. 2003 Aug 7;349(6):546-53
pubmed: 12904519
Lancet Oncol. 2013 Apr;14(4):297-305
pubmed: 23491275
Ann Surg. 2017 Sep;266(3):457-462
pubmed: 28650355
J Glob Oncol. 2018 Oct;4:1-8
pubmed: 30281378
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Breast Cancer Res Treat. 2019 Jan;173(2):429-438
pubmed: 30315437
Breast J. 2020 Jul;26(7):1330-1336
pubmed: 32506628
J Clin Oncol. 2005 Jul 1;23(19):4312-21
pubmed: 15994144
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
Cancer. 1998 Oct 1;83(7):1362-8
pubmed: 9762937
Ann Surg. 2021 Mar 1;273(3):474-482
pubmed: 33055590
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Gynecol Obstet Fertil. 2014 Jun;42(6):409-14
pubmed: 24861437
Ann Surg Oncol. 2021 Feb;28(2):920-929
pubmed: 32705512
Ann Surg. 2010 Sep;252(3):426-32; discussion 432-3
pubmed: 20739842
Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401
pubmed: 8092905
J Clin Oncol. 2021 Sep 20;39(27):3056-3082
pubmed: 34279999
Ann Surg Oncol. 2011 Sep;18(9):2407-12
pubmed: 21327455
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503097
Ann Surg Oncol. 2013 Aug;20(8):2556-61
pubmed: 23456432
Appl Health Econ Health Policy. 2023 Mar;21(2):275-287
pubmed: 36409454
Bull Cancer. 2022 Mar;109(3):268-279
pubmed: 34838310
J Clin Oncol. 2000 Jul;18(13):2553-9
pubmed: 10893286
Breast. 2019 Jun;45:89-96
pubmed: 30925382
Bull Cancer. 2020 Jun;107(6):672-685
pubmed: 31699399